Glaucoma: A disease of early cellular senescence

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 14, 2013, Pages

  Caprioli, Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Glaucoma; Optic nerve

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHAPERONE; HEAT SHOCK PROTEIN; MEMANTINE; PROTEASOME; TRANSFORMING GROWTH FACTOR BETA2; UBIQUITIN;

AGE; ALZHEIMER DISEASE; ARTICLE; CELL DEATH; CELLULAR SENESCENCE; CLINICAL TRIAL (TOPIC); CLOSED ANGLE GLAUCOMA; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LONGEVITY; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NERVE LESION; PRIORITY JOURNAL; RETINA GANGLION CELL; RISK FACTOR; SENESCENCE; STEM CELL;

EID: 84890351795     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12716     Document Type: Article

References (52)

1. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore eye survey. Am J Epidemiol. 1991;134:1102-1110.
2. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992;99:1499-1504.
3. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of openangle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103:1661-1669.
4. Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology. 1998;105:733-739.
5. Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences-The Rotterdam study. Invest Ophthalmol Vis Sci. 2000;41:3309-3321.
6. Leske MC, Connell AM, Schachat AP, Hyman L. Prevalence of open angle glaucoma: the Barbados eye study. Ophthalmology. 1994;112:821-829.
7. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119: 1819-1826.
8. Varma R, Wang D, Wu C, et al. Four-year incidence of openangle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2012;154:315-325.
9. Cedrone C, Mancino R, Cerulli A, Cesareo M, Nucci C. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res. 2008;173:3-14.
10. Kim JM, Jeoung JW, Bitrian E, et al. Comparison of clinical characteristics between Korean and Western normal-tension glaucoma patients. Am J Ophthalmol. 2013;155:852-857.
11. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005;24:612-637.
12. Liton PB, Challa P, Stinnett S, Luna C, Epstein DL, Gonzalez P. Cellular senescence in the glaucomatous outflow pathway. Exp Gerontol. 2005;40:745-748.
13. Liton PB, Gonzalez P, Epstein DL. The role of proteolytic cellular systems in trabecular meshwork homeostasis. Exp Eye Res. 2009;88:724-728.
14. Balazsi AG, Rootman J, Drance SM, Schulzer M, Douglas GR. The effect of age on the nerve fiber population of the human optic nerve. Am J Ophthalmol. 1984;97:760-766.
15. Leung CK, Yu M, Weinreb RN, et al. Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a prospective analysis of age-related loss. Ophthalmology. 2012;119:731-737.
16. Burgoyne CF. A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma. Exp Eye Res. 2011;93:120-132.
17. Girard MJ, Suh JK, Bottlang M, Burgoyne CF, Downs CJ. Scleral biomechanics in the aging monkey eye. Invest Ophthalmol Vis Sci. 2009;50:5226-5237.
18. Coudrillier B, Tian J, Alexander S, Myers KM, Quigley HA, Nguyen TD. Biomechanics of the human posterior sclera: ageand glaucoma-related changes measured using inflation testing. Invest Ophthalmol Vis Sci. 2012;53:1714-1728.
19. Ren R, Jonas JB, Tian G, et al. Cerebrospinal fluid pressure in glaucoma: a prospective study. Ophthalmology. 2010;117: 259-266.
20. Fleischman D, Berdahl JP, Zaydlarova J, Stinnett S, Fautsch MP, Allingham RR. Cerebrospinal fluid pressure decreases with older age. PLoS One. 2012;7:e52664.
21. Wostyn P, De Groot V, Van Dam D, Audenaert K, De Dayn PP. Senescent changes in cerebrospinal fluid circulatory physiology and their role in the pathogenesis of normal-tension glaucoma. Am J Ophthalmol. 2013;156:5-14.
22. Sivak JM. The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease. Invest Ophthalmol Vis Sci. 2013;54:871-880.
23. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmology. 1990;97:9-17.
24. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol. 2002; 47:165-168.
25. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077-1087.
26. Sun JH, Sung KR, Yun SC, et al. Factors associated with anterior chamber narrowing with age: an optical coherence tomography study. Invest Ophthalmol Vis Sci. 2012;53:2607-2610.
27. Kass MA, Gordon MO, Gao F, et al.; Ocular Hypertension Treatment Study Group. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol. 2010;128:276-287.
28. Ernest PJ, Schouten JS, Beckers HJ, Hendrikse F, Prins MH, Webers CA. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013;120:512-519.
29. Vajaranant TS, Wu S, Torres M, Varma R. The changing face of primary open-angle glaucoma in the United States: demographic and geographic changes from 2011 to 2050. Am J Ophthalmol. 2012;154:303-314.
30. Caprioli J. The importance of rates in glaucoma. Am J Ophthalmol. 2008;145:191-192.
31. Azarbod P, Mock D, Bitrian E, et al. Validation of point-wise exponential regression to measure the decay rates of glaucomatous visual fields. Invest Ophthalmol Vis Sci. 2012; 53:5403-5409.
32. Caprioli J, Mock D, Bitrian E, et al. A method to measure and predict rates of regional visual field decay in glaucoma. Invest Ophthalmol Vis Sci. 2011;52:4765-4773.
33. Artes PH, O'Leary N, Hutchison DM, et al. Properties of the statpac visual field index. Invest Ophthalmol Vis Sci. 2011;52: 4030-4038.
34. Varshavsky A. The ubiquitin system, an immense realm. Annu Rev Biochem. 2012;81:167-176.
35. Campello L, Esteve-Rudd J, Cuenca N, Nieto J. The ubiquitinproteasome system in retinal health and disease. Mol Neurobiol. 2013;47:790-810.
36. Ahn J, Piri N, Caprioli J, Munemasa Y, Kim SH, Kwong JM. Expression of heat shock transcription factors and heat shock protein 72 in rat retina after intravitreal injection of low dose N-methyl-D-aspartate. Neurosci Lett. 2008;433:11-16.
37. Joachim SC, Wax MB, Boehm N, Dirk DR, Pfeiffer N, Grus FH. Upregulation of antibody response to heat shock proteins and tissue antigens in an ocular ischemia model. Invest Ophthalmol Vis Sci. 2011;52:3468-3474.
38. Lan YW, Ishii Y, Palmer KE, Bristow KQ, Caprioli J, Kwong JMK. 2-Deoxy-D-glucose protects retinal ganglion cells against excitotoxicity. Neuroreport. 2003;14:2369-2372.
39. Izzotti A, Longobardi M, Cartiglia C, Rathschuler F, Sacca SC. Trabecular meshwork gene expression after selective laser trabeculoplasty. PLoS One. 2011;6:e20110.
40. Kelley MJ, Rose AY, Keller KE, Hessle H, Samples JR, Acott TS. Stem cells in the trabecular meshwork: present and future promises. Exp Eye Res. 2009;88:747-751.
41. Du Y, Roh DS, Mann MM, Funderburgh ML, Funderburgh JL, Schuman JS. Multipotent stem cells from trabecular meshwork become phagocytic TM cells. Invest Ophthalmol Vis Sci. 2012; 53:1566-1575.
42. Yu AL, Birke K, Moriniere J, Welge-Lussen U. TGF-b2 induces senescence-associated changes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2010;51:5718-5723.
43. Harper MM, Grozdanic SD, Blits B, et al. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. Invest Ophthalmol Vis Sci. 2011;52:4506-4515.
44. Ramsden CM, Powner MB, Carr AJ, Smart MJ, da Cruz L, Coffey PJ. Stem cells in retinal regeneration: past, present and future. Development. 2013;140:2576-2585.
45. Singhal S, Bhatia B, Jayaram H, et al. Human Müller glia with stem cell characteristics differentiate into retinal ganglion cell (RGC) precursors in vitro and partially restore RGC function in vivo following transplantation. Stem Cells Transl Med. 2012;1: 188-199.
46. Kwong JMK, Quan A, Kyung H, Piri N, Caprioli J. Quantitative analysis of retinal ganglion cell survival with Rbpms immunolabeling in animal models of optic neuropathies. Invest Ophthalmol Vis Sci. 2011;52:9694-9702.
47. Nagaraju M, Saleh M, Vittorio P. IOP-dependent retinal ganglion cell dysfunction in glacomatous DBA/2J mice. Invest Ophthalmol Vis Sci. 2007;48:4573-4579.
48. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laserinduced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849-2855.
49. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151:671-681.
50. Cordeiro MF, Levin LA. Clinical evidence for neuroprotection in glaucoma. Am J Ophthalmol. 2011;152:715-716.
51. Baltan S, Inman DM, Danilov CA, Morrison RS, Calkins DJ, Horner PJ. Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration. J Neurosci. 2010;30:5644-5652.
52. Yücel Y. Central nervous system changes in glaucoma. J Glaucoma. 2013;22(suppl 5):S24-S25.